The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …

Background The proportion of incident cases of HPV-attributable cancers is highest in the
low-and middle-income countries (LMICs) but many are yet to initiate HPV vaccination …

During the last 12 years, over 80 countries have introduced national HPV vaccination
programs. The majority of these countries are high or upper-middle income countries. The …

The current global novel coronavirus disease 2019 (COVID-19) pandemic threatens to
derail the uptake of human papillomavirus (HPV) vaccination in low-and lower-middle …

Background Immunization directly impacts health (SDG3) and brings a contribution to 14 out
of the 17 Sustainable Development Goals (SDGs), such as ending poverty, reducing hunger …

Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as
cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that …

With major advances in understanding the infectious etiology of cervical cancer, preventive
medicine has obtained highly promising new tools. Human papillomavirus (HPV) vaccines …

Background Adolescent vaccination has received increased attention since the Global
Vaccine Action Plan's call to extend the benefits of immunisation more equitably beyond …

Globally, human papillomavirus (HPV) infection is one of the most common sexually
transmitted infection. HPV is linked to at least five malignancies including vulvar, vaginal …

Objective To synthesise lessons learnt and determinants of success from human
papillomavirus (HPV) vaccine demonstration projects and national programmes in low-and …